Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target by unknown
ORIGINAL ARTICLE
Overexpression of LARP1 predicts poor prognosis of colorectal
cancer and is expected to be a potential therapeutic target
Ling Ye1 & Sheng-tao Lin1 & Yu-shuai Mi1 & Yuan Liu1 & Yang Ma1 & Hui-min Sun2 &
Zhi-hai Peng1 & Jun-wei Fan1
Received: 18 April 2016 /Accepted: 6 September 2016 /Published online: 10 September 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract This study investigated the significance of La-
related protein 1 (LARP1) in the development and progression
of colorectal cancer (CRC). Quantitative real-time polymerase
chain reaction and Western blot analyses were carried out to
determine the mRNA and protein expression of LARP1 in
CRC tumor tissues and paired adjacent normal mucosa. The
express ion of LARP1 was upregula ted in CRC.
Immunohistochemical analysis using tissue microarray was
performed. A positive correlation between LARP1 and prolif-
erating cell nuclear antigen (PCNA) in the area of proliferation
was observed using the Spearman’s correlation coefficient test
(r = 0.332, P < 0.01). The elevated expression of LARP1
significantly correlated with T stage (P = 0.02), N stage
(P = 0.006), M stage (P < 0.001), American Joint
Committee on Cancer (AJCC) stage (P = 0.04), differentiation
rank (P < 0.001), and PCNA level (P < 0.001). In addition, the
inhibitory effect of LARP1 knockdown on CRC cell prolifer-
ation was demonstrated using Cell Counting Kit-8 (CCK8)
and colony-forming cell (CFC) assays. Multivariate analysis
showed that LARP1 was an independent prognostic factor for
overall survival (OS; hazard rate (HR) = 0.244; 95 % confi-
dence interval (CI), 0.078–0.769; P = 0.016) and disease-free
survival (DFS; HR = 0.281; 95%CI, 0.086–0.917;P = 0.035)
in CRC patients. LARP1 plays an important role in the pro-
liferation of colorectal cancer and represents a new prognostic
indicator.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers
worldwide, with a high incidence and mortality [1]. In China,
CRC is the fourth most common cancer and the fifth leading
cause of death among all types of human cancer [2, 3].
Although CRC has a very high cure rate following surgical
resection followed by multidisciplinary treatment (radiation
and systemic chemotherapy) in the early stages, the high rate
of relapse and distant metastasis still threaten a large percent-
age of patients [4, 5]. Efforts have been made to elucidate the
genetic and molecular characteristics of CRC, for prognosis
and response to targeted treatment [3, 5]. Tumor proteins such
as P53, KRAS, and others have been associated with colorec-
tal cancer progression and prognosis. However, tumor hetero-
geneity suggests the need for new markers of CRC [4, 6].
Candidate diagnostic markers in colon cancer were
screened by combining experimental and bioinformatics ap-
proaches. Using laser capture microdissection, we obtained
purified cell populations from heterogeneous tissues and
found that La-related protein 1 (LARP1), an RNA-binding
protein (RBP), was overexpressed in colorectal cancer tissues
compared with paired normal specimens [7].
The LARP subfamilies comprising La, LARP1, LARP1b,
LARP4, LARP4b, LARP6, and LARP7 play a significant role
in transcription and/or mRNA translation [8, 9]. The members
of the LARP family lack enzymatic domains but carry a La
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motif and a nearby RNA recognition motif with location vary-
ing among the different LARP proteins [8]. RBPs are impor-
tant posttranscriptional regulators, with a key role in gene
expression in a variety of human tumors [10–13]. LARPs
are one of the RBPs that promote cell migration, invasion,
and tumorigenesis in vivo [14]. Therefore, a comprehensive
understanding of LARPs enables early detection of new bio-
markers and facilitates the development of a strategy for can-
cer prevention and therapy.
LARP1 gene, which is located on chromosome 5q34, en-
codes a 1096-amino acid protein [15]. LARP1 carries a unique
and highly conserved DM15 region, with unknown function
[16]. However, DM15 has been suggested to mediate nucleic
acid binding, which may be associated with oncogenesis [9,
17]. Recently, LARP1 was shown to be overexpressed in cer-
vical and non-small cell lung cancers, with increased expres-
sion correlated with cancer progression and poor prognosis
[14]. As a promising biomarker, the expression of LARP1 is
closely related to poor prognosis of early-stage and alpha-
fetoprotein-normal hepatocellular carcinoma (HCC) patients
[18]. Recently, it has been found that downregulation of
LARP1 expression in endometrial cancer and lung cancer cell
lines was associated with decreased cell proliferation [19].
However, the role of LARP1 in the prognosis and cellular
proliferation of colorectal cancer has yet to be defined.
Uncontrolled cell proliferation is considered to be an im-
portant feature of malignancy and is closely related to cancer
progression. A previous study demonstrated that LARP1 is
associated with the proliferation of endometrial cancer and
lung cancer lines [19]. In this study, we explored the effect
of LARP on the proliferation of colorectal cancer cells. As the
accessory protein of DNA polymerase δ, Proliferating cell
nuclear antigen (PCNA) plays an important role in cell prolif-
eration, DNA replication, and repair [20]. In addition, PCNA
also interacts with proteins involved in cell cycle regulation
and checkpoint control [21]. The crucial role of PCNA in
cellular proliferation supports its frequent use as a marker of
tumor cell proliferation [22, 23]. Therefore, we combined
PCNA with LARP1 to examine the effect of LARP1 on
CRC cell proliferation.
This study initially evaluated the expression of LARP1 in
CRC tissues and adjacent normal specimens to investigate the
significance of LARP1 in the development and progression of
CRC. Furthermore, our study determined the expression of
LARP1 and PCNA using immunohistochemical analysis with
CRC tissue microarrays (TMAs). We investigated the rela-
tionship with clinic pathological features as well as patient
survival to illustrate the possibility of LARP1 as a prognostic
marker in CRC. The correlation between LARP1 and PCNA
in cancer cell proliferation was determined using the
Spearman’s correlation coefficient test. The influence of
LARP1 on CRC cell proliferation was studied after silencing
the expression of LARP1 using short hairpin RNA (shRNA).
Materials and methods
Patients and tissue samples
Tissue samples were obtained from patients who had un-
dergone radical resection at the General Surgery
Department of Shanghai General Hospital. No chemother-
apy or radiation therapy was applied to these patients
before radical resection. We collected a total of 40 cases
of colorectal cancer specimens between December 2014
and September 2015. The diagnosis was confirmed by
two pathologists, and the cancer staging was determined
based on pathological findings according to the American
Joint Committee on Cancer (AJCC). All the CRC and
corresponding adjacent normal mucosa specimens
were collected and preserved after the approval of
Institutional Research Ethics Committee of Shanghai
Jiao Tong University Affiliated Shanghai General
Hospital. All of the 40 patients in the study signed the
informed consent. The CRC tissues and adjacent normal
mucosae (at least 10 cm away from the primary site) were
obtained after surgical resection and immediately frozen
in liquid nitrogen and stored at −80 °C to extract RNA
and protein later.
RNA extraction and quantitative real-time polymerase
chain reaction
The total RNA was extracted from cultured cells, tumor tis-
sues, and paired normal mucosa from 40 colorectal cancer
patients according to protocols of the manufacturer (TRIzol,
TaKaRa, Japan). The first-strand cDNAwas synthesized using
1 μg of total RNA by a RevertAid First Strand cDNA
Synthesis Kit (Fermentas, Lithuania). Reverse transcription-
polymerase chain reaction (RT-PCR) was performed using a
ViiA 7 Real-Time PCR System (Life Technology, New York,
USA), according to the manufacturer’s protocol. The primer
sequences used were as follows: LARP1 sense 5′-GCAA
CCTAAAGACACTAC-3 ′ and antisense 5 ′-CCTC
TTCTTCACTTCAATC-3 ′ , PCNA sense 5 ′-GTAC
CTGAACTTCTTTACAAA-3′ and antisense 5′-TGCC
TAAGATCCTTCTTC-3 ′, cyclinD1 sense 5 ′-GCTG
CGAAGTGGAAACCA-3 ′ and antisense 5 ′-CCTC
CTTCTGCACACATTTG-3′, and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) sense 5′-GGAA
GCTTGTCATCAATG-3 ′ and ant isense 5 ′ -CCCC
ACTTGATTTTGGAG-3′. The amplification conditions were
as follows: 1 cycle of 2 min at 95 °C followed by 40 cycles of
10 s at 95 °C, 30 s at 60 °C, and 30 s at 72 °C. All experiments
were performed in triplicate. The relative quantities of the
expression of LARP1 were calculated by 2−ΔΔCt (cycle
threshold) values, with GAPDH as an internal control.
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Cell culture and plasmids
The CRC cells HCT8 and RKO were purchased from the
Type Culture Collection of the Chinese Academy of
Sciences (Shanghai, China). All the cells were cultured at
37 °C under a moist atmosphere with 5%CO2 andmaintained
in Dulbecco’s modified Eagle medium supplemented with
10 % fetal bovine serum (Gibco, USA), 1 % streptomycin,
and penicillin. The shRNA plasmid for LARP1 and the
control-shRNA plasmid were purchased from Gene Pharma
Company (Shanghai, China). For plasmid transfection,
4 × 104 cells/well in six-well plates were cultured overnight
and then transfected with plasmids using Lipofectamine 2000
(Invitrogen, CA, USA), following the manufacturer’s proto-
cols. Stable clones of HCT8 and RKO cells expressing
LARP1 shRNA or control shRNAwere obtained by puromy-
cin selection. The shRNA target sequence for LARP1 was 5′-
GCCAGTCTCAGGAGATGAACA-3′. The control-shRNA
target sequence was 5′-TGTTCATCTCCTGAGACTGGC-3′.
Western blot analysis
Total protein was isolated using a radioimmunoprecipitation
assay lysis buffer (Beyotime Biotechnology, China) according
to the manufacturer’s instruction. Then, the concentration of
extracted protein was measured using the bicinchoninic acid
(BCA) protein assay kit (Beyotime Biotechnology). The same
amount of protein (30 μg) was dropped into 10 % sodium
dodecyl sulfate (SDS)-polyacrylamide gel for electrophoresis
and then transferred onto polyvinylidene difluoride (PVDF)
membranes. The membranes were blocked with 5 % fat-free
milk in Tris-buffered saline and 0.1 % Tween 20 solution at
room temperature, and then incubated with primary antibody
against LARP1 (1:2000 dilution; Abcam, Cambridge, UK)
and GAPDH (1:1000 dilution; Abcam, Cambridge, UK) at
4 °C overnight. Subsequently, the membranes were incubated
with secondary antibody (1:5000 dilution; Abgent, San
Diego, CA, USA), which has a role of horseradish peroxide
(HRP)-tagged detection at room temperature for 2 h. Images
of proteins were displayed using an enhanced chemilumines-
cence reagent (Applygen Technologies Inc., Beijing, China).
The Quantity One software (Bio-Rad, California, USA) was
used to quantitate the gray scale of each protein strips.
Immunohistochemistry on tissue microarray
The TMA containing 117 paired CRC specimens was con-
structed in cooperation with Xin Chao Company (Shanghai,
China). Tumors were resected from patients between
May 2005 and March 2007. The follow-up lasted until
December 2014. The median follow-up time in survivors
was 63.5 months (range, 4–88 months). The TMA data in-
clude 55 men and 62 women with a mean age of 66.32 years
(range, 26–89 years). After being dewaxed and rehydrated in
xylene and a graded series of ethanol, antigen retrieval for
tissue sections were implemented using 0.01M sodium citrate
buffer (pH 6.0). Then, the tissue sections were incubated in the
dark with the primary antibody against LARP1 (1:500 dilu-
tion; Abcam, Cambridge, UK) or PCNA (1:10,000 dilution;
Abcam, Cambridge, UK) for 16 h at 4 °C. The primary anti-
body was detected using an HRP-conjugated secondary anti-
body (Gene Tech, Shanghai, China) for 30 min at room tem-
perature. The immunoreactivity was evaluated independently
by two pathologists who were blind to the prognosis of pa-
tients. The evaluation included both the intensity and the area
of staining. Staining intensity for LARP1 scores were as fol-
lows: 0 for negative, 1 for weak, 2 for moderate, and 3 for
strong. The extent of staining was calculated according to the
percentage of the cells stained positively; scores were as fol-
lows: 0 (0 %), 1 (1–25 %), 2 (26–50 %), 3 (51–75 %), and 4
(76–100 %). After multiplying the staining intensity score by
the staining extent score, the specimens were divided into two
groups based on the final score: low (0–6) and high (7–12).
The PCNA index was based on the percentage points of the
positive nuclear staining cells, and the specimens were divid-
ed into two groups based on this: low (less than 10 % of cells
with positive nuclei) and high (more than 10 % of cells with
positive nuclei).
Cell proliferation assays
The cell proliferation ability was measured using Cell
Counting Kit-8 (CCK8) (Dojindo, Japan) according to the
instructions of the manufacturer. In simple terms, cells were
seeded into 96-well plates (2 × 103 cells/well) in triplicate. At
the appropriate time (12, 24, 36, 48, 60, 72, 96 h), the cells
were incubated with 10-μL CCK-8 solution for 2 h at 37 °C
under a moist atmosphere with 5 % CO2. The absorbance of
450 nm was measured using the Gen5 microplate reader
(BioTek, Vermont, USA).
Plate colony formation assays
In the plate colony formation assays, 1000 log-phase cells per
well were seeded in six-well plates and then cultured at 37 °C
under a moist atmosphere with 5 % CO2 for 2 weeks. After
fixing with methyl alcohol for 15 min, the cells were stained
with Giemsa solution for 20 min. Then, counting and
photographing were carried out for colonies of each well.
All assays were repeated independently in triplicate.
Statistical analysis
The SPSS statistical software program version 22 (SPSS, IL,
USA) was used for statistical analysis. The two-tailed
Student’s t test was used for continuous variables. The χ2 test
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or Fisher’s exact test for categorical data was used to analyze
the relationship between LARP1 and clinicopathological fea-
tures. The disease-free survival (DFS) and overall survival
(OS) rates were defined as the interval from the initial surgery
to clinically or radiologically proven recurrence/metastasis
and death, respectively. The Kaplan–Meier method was used
to calculate the survival rates, and the differences between the
survival curves were examined by the log-rank tests. Cox
proportional hazards models were applied to estimate the ef-
fects of the expression of LARP1 and CRC clinicopathologi-
cal variables on survival in univariate and multivariate analy-
ses. P < 0.05 was considered statistically significant.
Results
Significant upregulation of the expression levels of LARP1
in human CRC
The gene expression of LARP1 at the mRNA level was eval-
uated by the real-time PCR analysis of 40 pairs of colorectal
cancer tissues and their paired adjacent normal mucosa. As
shown in Fig. 1a, 19 (47.5 %) colorectal cancer tissues
showed at least a twofold increase at the LARP1 mRNA level
compared with the adjacent normal specimens. The mean rel-
ative quantification of LARP1 in the colon cancer tissue spec-
imens (2.61 ± 0.55) was significantly higher than that in the
normal tissue specimens (1.14 ± 0.23, P < 0.001 Student’s t
test). The expression of LARP1 at the protein level was also
confirmed using Western blot analysis. The LARP1 protein
levels of tumor tissue specimens were significantly higher
than those of the adjacent normal mucosa tissue (Fig. 1b).
Thus, the expression of LARP1was elevated at both transcrip-
tional and posttranscriptional levels.
Association of the expression of LARP1 and PCNA
in colon cancer with clinicopathological factors
Among the 117 CRC tissues and paired adjacent normal spec-
imens on TMA, the immunohistochemical analysis of the ex-
pression of LARP1 and PCNA was performed. LARP1 was
expressed in the cytoplasm rather than in the cell nucleus,
while PCNA only expressed in the nucleus (Fig. 2). LARP1
showed various expression levels in colorectal tumor tissues,
including weak, moderate, and strong. A conspicuous expres-
sion of LARP1 was apparent in 61 (52.1 %) of 117 colon
cancer tissue specimens. The association between the expres-
sion of LARP1 and PCNAwith clinicopathological factors is
summarized in Table 1. The upregulated expression of
LARP1 significantly correlated with T stage (P = 0.02), N
stage (P = 0.006), M stage (P < 0.001), AJCC stage
(P = 0.04), and differentiation rank (P < 0.001). The overex-
pression of PCNA was significantly associated with T stage
(P = 0.012), N stage (P < 0.001), M stage (P = 0.01), and
AJCC stage (P ≤ 0.001). Furthermore, the expression of
LARP1 was higher in specimens in which PCNA staining
was positive than those in which PCNA stainingwas negative.
The positive correlation between LARP1 and PCNA in the
area of proliferation was observed by using the Spearman’s
correlation coefficient test (r = 0.332, P < 0.01) (Table 2).
Overexpression of LARP1 alone or combined with PCNA
predicts poor prognosis
The Kaplan–Meier analysis was used to show the relationship
between patient survival (OS and DFS) and the expression of
LARP1 or PCNA. The Kaplan–Meier plot showed that the
patients with the elevated expression of LARP1 had a poorer
OS (P < 0.001) and DFS (P < 0.01) than did the patients with
LARP1-low tumors (Fig. 3a). The patients with an elevated
expression of PCNA had a lower OS (P < 0.001) and DFS
(P = 0.024) than did the patients with low PCNA expression
(Fig. 3b). Furthermore, the samples were divided into the fol-
lowing three groups based on the concomitant expression of
LARP1 and PCNA proteins: group 1, tumors exhibiting high
expression of both proteins (LARP1+/PCNA+); group 2, tu-
mors exhibiting high expression of only one protein
(LARP1+/PCNA−, or LARP1−/PCNA+); and group 3, tu-
mors exhibiting low expression of both proteins (LARP1
−/PCNA−). Notably, a better OS and DFS were obtained in
group 3 compared with group 2, while group 1 had the lowest
Fig. 1 LARP1 expression in colorectal cancer tissues and adjacent
normal mucosa. a Relative expression of LARP1 gene in 40 matched
colorectal cancer tissue specimens compared with normal mucosa
samples. The fold change of quantitative real-time polymerase chain
reaction (RT-PCR) was calculated using the logarithmic scale of
2−ΔΔCt. b Western blot of LARP1 protein expression in representative
four paired colorectal tumor tissues
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OS and DFS compared with groups 2 and 3 (P < 0.01)
(Fig. 3c).
A univariate analysis was performed using the Cox propor-
tional hazards model. The result showed that tumor depth,
AJCC stage, LNM stage, distant metastasis, vascular invasion,
and expression of LARP1 and PCNA were associated with
decreased OS (Table 3); all these characteristics, except tumor
depth, were associated with decreased DFS (Table 4). The
multivariate analysis demonstrated that the expression of
LARP1 is an independent prognostic factor for OS
(HR = 0.244; 95 % CI, 0.078–0.769; P = 0.016) and DFS
(HR = 0.281; 95 % CI, 0.086–0.917; P = 0.035).
Knockdown of the expression of LARP1 by shRNA
inhibits CRC cell proliferation
To further determine the potential effects of LARP1 on CRC
cell proliferation, the RKO and HCT8 cell lines were treated
with LARP1-shRNA to knockdown the expression (Fig. 4a).
To evaluate the effects of LARP1 knockdown on CRC cell
proliferation, the quantitative PCR analysis was used to detect
the expression of proliferation-related genes (PCNA; cyclin
D1). The expression level of PCNA and cyclin D1 mRNA
was downregulated in LARP1-shRNA cells (Fig. 4b). Then,
CCK-8 and plate colony formation assays were used to estimate
the role of LARP1 in CRC cell growth. As shown in Fig. 4c, the
LARP1 knockdown cells were significantly reduced in cell
proliferation compared with that of control shRNA cells.
Fig. 2 Immunohistochemical staining of LARP1 and PCNA expression
in normal and colorectal cancer tissues. Representative images of LARP1
and PCNA expression in normal colonic epithelium (a, e), highly
differentiated tumor tissues (b, f), moderately differentiated tumor
tissues (c, g), and poorly differentiated cancer (d, h). The expression of
LARP1 was higher in specimens with intensely positive PCNA staining.
Original magnification ×200 (×40 for inset images)
Table 1 Association between clinicopathologic characteristics and
LARP1 or PCNA protein expression
LARP1 P value PCNA P value
Low High Low High
Age (years)
<65 50 25 25 21 29
≥65 67 31 36 0.689 34 33 0.348
Gender
Male 55 26 29 33 22
Female 62 30 32 0.904 26 36 0.243
Location
Left 64 33 31 38 26
Others 53 23 30 0.379 18 35 0.378
T stage
T1 + T2 23 16 7 18 5
T3 + T4 94 40 54 0.02* 36 58 0.012*
N stage
N0 64 38 26 44 20
N1 + N2 53 18 35 0.006* 23 30 0.001*
M stage
M0 102 55 47 49 53
M1 15 1 14 0.001* 5 10 0.01*
AJCC stage
I + II 63 33 30 40 23
III + IV 54 20 34 0.04* 15 39 0.001*
Differentiation
Well + moderate 98 54 44 50 48
Poorly 19 2 17 0.000* 5 14 0.048*
Vessel invasion
No 113 42 71 50 63
Yes 4 2 2 1.000 0 4 1.000
P values are based on chi-square test or Fisher’s test
AJCC American Joint Committee on Cancer
*P < 0.05 was considered significant
Table 2 The association between LARP1 and PCNA protein
expression
Tissue sample PCNA expression P value r
Negative Positive
LARP1 negative 36 20
LARP1 positive 19 42 <0.001* 0.332
* P < 0.05 was considered significant
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Furthermore, the ability of colony formation in the LARP1
knockdown cells were also reduced compared with that in con-
trol shRNA cells (P < 0.01) (Fig. 4d). These data showed that
LARP1 contributed to CRC cell proliferation.
Discussion
A great deal of evidence suggests that the LARP family is
dysregulated in a variety of cancers [9]. LARP1 was the
first member of the LARP family to be associated with
oncogenesis [8]. It was first discovered in Drosophila. It
plays a key role in embryogenesis, oogenesis, spermato-
genesis, mitotic spindle formation, mitochondrial segrega-
tion, and cell cycle progression [24–26]. Although
LARP1 plays an important role in tumorigenesis and pro-
gression of cervical cancer, non-small cell lung cancer,
Table 3 Univariate and
multivariate Cox proportional
hazard models for overall survival
(OS)
Variable Univariate Multivariate
HR (95 % CI) P value HR (95 % CI) P value
LARP1
Low 1 1
High 0.154(0.059–0.401) <0.001* 0.244(0.078–0.769) 0.016*
PCNA
Low 1 1











T1 + T2 1 1
T3 + T4 0.121(0.016–0.886) 0.038* 0.303(0.040–2.316) 0.250
N stage
N0 1 1
N1 + N2 0.105(0.040–0.272) <0.001* 0.527(0.065–4.268) 0.548
M stage
M0 1 1
M1 0.024(0.010–0.059) <0.001* 0.095(0.032–0.283) <0.001*
AJCC stage
I + II 1 1
III + IV 0.082(0.029–0.234) <0.001* 0.338(0.031–3.709) 0.375
Differentiation
Well + moderate 1 1
Poorly 0.134(0.066–0.273) <0.001* 0.754(0.301–1.889) 0.546
Vessel invasion
No 1 1
Yes 0.230(0.070–0.758) 0.016* 0.208(0.052–0.826) 0.026*
HR hazard ratio; CI confidence interval
*P < 0.05 was considered significant
Fig. 3 Kaplan–Meier survival analyses and log-rank test. a Disease-free
survival (DFS) and overall survival (OS) of 117 patients correlated with
LARP1 expression were determined by immunohistochemical staining of
tissue microarrays. b DFS and OS were significantly higher in patients
with PCNA-negative than in PCNA-positive tumors (P < 0.05). c DFS
and OS were significantly lower in patients with tumors expressing high
rather than low levels of both LARP1 and PCNA (P < 0.01)
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HCC, and prostate cancer [10, 18, 27, 28], the biological
function and prognostic value of LARP1 expression in
human colon cancer are still unknown.
This study identified the aberrant upregulation of LARP1
mRNA and protein in CRC tissues compared with paired nor-
mal specimens. Using immunohistochemical analysis, the up-
regulation of LARP1 in CRC tissues was found to be signif-
icantly associated with clinical pathological characteristics,
such as tumor size, AJCC stage, depth of invasion, lymph
node metastasis, distant metastasis, and tissue differentiation.
The results demonstrated that LARP1 was a potential bio-
marker of colorectal cancer. As an important cell proliferation
marker, PCNA plays an essential role in DNA replication and
repair [20]. Its expression and distribution are closely associ-
ated with the rate of cellular proliferation and DNA synthesis
[29]. This study found that the elevated expression of LARP1
correlated positively with PCNA expression, suggesting that
LARP1 mediated cancer cell proliferation.
We carried out functional experiments to demonstrate the
hypothesis that LARP1 promoted CRC cell proliferation.
CCK-8 assays were used to illustrate the effect of LARP1
on CRC cell proliferation. The results showed that LARP1
knockdown in RKO and HCT8 cells inhibited cell prolifera-
tion. Using quantitative real-time PCR assays, we found that
Table 4 Univariate and
multivariate Cox proportional
hazard models for disease free
survival (DFS)
Variable Univariate Multivariate
HR (95 % CI) P-value HR (95 % CI) P-value
LARP1
Low 1 1
High 0.210(0.079–0.560) 0.002* 0.281(0.086–0.917) 0.035*
PCNA
Low 1 1











T1 + T2 1
T3 + T4 0.148(0.020–1.097) 0.062
N stage
N0 1 1
N1 + N2 0.101(0.035–0.296) <0.001* 0.174(0.055–0.551) 0.003*
M stage
M0 1 1
M1 0.041(0.015–0.113) <0.001* 0.145(0.038–0.543) 0.004*
AJCC stage
I + II 1 1
III + IV 0.119(0.039–0.334) <0.001* 0.338(0.031–0.709) 0.003*
Differentiation
Well + Moderate 1 1
Poorly 0.177(0.078–0.405) <0.001* 0.743(0.237–2.332) 0.611
Vessel invasion
No 1 1
Yes 0.219(0.051–0.937) 0.041* 0.169(0.032–0.903) 0.038*
HR: Hazard ratio; CI: Confidence interval
*P < 0.05 was considered significant
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the expression of LARP1 and proliferation-related genes
(PCNA; cyclin D1) was significantly downregulated in
LARP1 knockdown cells. Furthermore, the colony formation
ability was significantly decreased in LARP1-silenced cells.
Our findings show that downregulation of LARP1 inhibits cell
proliferation in CRC. It is well known that molecular targets
play an important role in cancer therapy. The effect on cellular
proliferation indicates that LARP1 is a desirable therapeutic
target. Studies suggest that the phosphatidylinositol-3-kinase
(PI3K)/AKT/mammalian target of rapamycin (mTOR) path-
way promotes mRNA translation and increases protein syn-
thesis, which affects both cell growth and proliferation [14,
19, 30]. It has been demonstrated that LARP1 expression
correlates with poor prognosis of non-small cell lung cancer
and promotes cellular proliferation by interacting with mTOR
[10, 14, 19]. Additional studies are needed to investigate
whether LARP1 mediated cellular proliferation and prognosis
of colorectal cancer by interacting with mTOR.
To our knowledge, this study showed for the first time that
overexpression of LARP1 alone or combined with PCNA
predicts poor prognosis of patients with CRC. The Kaplan–
Meier survival analysis showed that postoperative patients
with high expression of LARP1 manifested poor OS
(P < 0.001) and DFS (P < 0.01). In addition, the multivariate
analysis using Cox proportional hazards model revealed that
the expression of LARP1 is an independent prognostic factor
for OS and DFS.
Nonetheless, this study also have some limitations. First, the
interaction between LARP1 and mTOR in CRC cells was not
validated in the present study. Second, the effects of LARP1
Fig. 4 LARP1 knockdown inhibits colorectal cancer cell proliferation. a
LARP1 level in stable knockdown HCT8 and RKO cell lines was
assessed by Western blot. Grayscale values were analyzed using
Quantity One software (n = 3, P < 0.05). b expression of proliferation-
related genes was inhibited in LARP1 knockdown cells according to real-
time PCR (n = 3; P < 0.05). c, d Effects of LARP1 knockdown on cell
growthwere evaluated byCell Counting Kit-8 assays (c) and plate colony
formation assays (d) (n = 3; P < 0.05)
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were not explored in vivo. Therefore, further studies are need-
ed to confirm the hypothesis that LARP1 is a prognostic bio-
marker and a potential target for CRC therapy.
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